// App-Quantinova.ai

2736 : Fludarabine, Mitoxantrone and Rituximab (FMR) Regimen in Previously Untreated Patients with Indolent Non-Hodgkin Lymphoma: Efficacy, Safety and PET Data On 285 Patients.

Researchers

Presenter

  • Cinzia Pellegrini

Principal Investigators

  • Enrico Derenzini

  • Alessandro Broccoli

  • Letizia Gandolfi

  • Vittorio Stefoni

  • Beatrice Casadei

  • Federica Quirini

  • Lisa Argnani

Medical Centers

  • Department of Hematology and Oncology, Policlinico S.Orsola-Malpighi, Bologna, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Mucosa-associated lymphoid tissue lymphoma

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Familial non-Hodgkin lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Mitoxantrone

  • fludarabine tablet

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved